Pharmaceutical company · MRK

Merck
clinical trial
pipeline

Registry checked

Published

Oncology is the largest mapped primary therapeutic group, with 151 of 236 active trials. This ranking covers mapped groups only. Pembrolizumab is linked to 38 distinct active studies, with 13 Phase 2, 24 Phase 3, 1 Phase 4. Sacituzumab tirumotecan is linked to 18 distinct active studies, with 1 Phase 1, 3 Phase 2, 14 Phase 3.

Phase 2 study NCT05468697 in Renal Cell Carcinoma lists estimated primary completion on 22 December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

236active trials
as lead sponsor
  • Phase 132
  • Phase 292
  • Phase 3107
  • Phase 43
  • Phase not recorded2

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

4734 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved earlier by 969 days

2032-04-15 (estimated)2029-08-20 (estimated)
15 Apr 203220 Aug 2029

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085 · ClinicalTrials.gov
Recorded by ComplyRx
31 Oct 2026
Registry last updated
30 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020200022
2026-10-031000011
2026-10-040000000
2026-10-050000000
2026-10-061210154
2026-10-070000000
2026-10-081010133
2026-10-091100022
2026-10-102110042
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-151000011
2026-10-160000000
2026-10-171000011
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-212410295
2026-10-222110043
2026-10-231200254
2026-10-241000011
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-281100022
2026-10-290100121
2026-10-301000232
2026-10-310100122
Type totals161650104734 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Pembrolizumab

Keytruda

38
Active trials
12
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 213
  • Phase 324
  • Phase 41
  • Phase not recorded0
Studied condition
Advanced Cancer · Advanced Solid Tumors · Anal Cancer
Next primary completion
20 November 2026 · estimated
Open drug

Sacituzumab tirumotecan

Canonical investigational asset

18
Active trials
10
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 23
  • Phase 314
  • Phase 40
  • Phase not recorded0
Studied condition
Biliary Tract Cancer · Bladder Cancer · Breast Neoplasms
Next primary completion
10 May 2027 · estimated
Open drug

Belzutifan

welireg

12
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 25
  • Phase 36
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Gastrointestinal Stromal Tumor · Carcinoma, Renal Cell · HIF-2α Mutated Cancers
Next primary completion
22 December 2026 · estimated
Open drug

Tulisokibart

Canonical investigational asset

10
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 27
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Arthritis, Rheumatoid · Colitis, Ulcerative · Crohn Disease
Next primary completion
17 February 2027 · estimated
Open drug

Calderasib

Canonical investigational asset

9
Active trials
9
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 23
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Solid Tumors · Colon Adenocarcinoma · Lung Neoplasm Malignant
Next primary completion
Not reported
Open drug

Sotatercept

Canonical investigational asset

8
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 24
  • Phase 32
  • Phase 42
  • Phase not recorded0
Studied condition
Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Pulmonary Hypertension
Next primary completion
Not reported
Open drug

223 of 236 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 223 of 236 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Merck trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Pembrolizumab

NCT04634877

Phase 3 · Active, not recruiting

Trial source and qualifications

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

3 candidate observations · 1 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-09-18 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 10 Jan 2021 · actual
Primary completion: 20 Nov 2026 · estimated
Study completion: 20 Nov 2026 · estimated

2021202220232024202520262027202820292030
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
Belzutifan

NCT05468697

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

6 candidate observations · 2 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

4 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-08-21 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • pc date moved · Recorded 2026-10-28 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 10 Aug 2022 · actual
Primary completion: 22 Dec 2026 · estimated
Study completion: 22 Dec 2026 · estimated

2021202220232024202520262027202820292030
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Sacituzumab Govitecan

NCT05609968

Phase 3 · Active, not recruiting

Trial source and qualifications

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 06 Feb 2023 · actual
    Primary completion: 12 Jan 2027 · estimated
    Study completion: 23 Aug 2028 · estimated

    2021202220232024202520262027202820292030
    Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
    9vHPV Vaccine

    NCT04199689

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

    Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    Start clipped at the display horizon.

    2 candidate observations · 1 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

    • pc date moved · Recorded 2026-10-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 27 Feb 2020 · actual
    Primary completion: 15 Jan 2027 · estimated
    Study completion: 13 Aug 2027 · estimated

    2021202220232024202520262027202820292030
    Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
    Pembrolizumab

    NCT04241185

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

    Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon, end-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    Start clipped at the display horizon. End clipped at the display horizon.

    3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 19 May 2020 · actual
      Primary completion: 31 Jan 2027 · estimated
      Study completion: 01 Nov 2031 · estimated

      2021202220232024202520262027202820292030
      Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
      Pembrolizumab

      NCT03407144

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

      Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      Start clipped at the display horizon.

      2 candidate observations · 1 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

      • pc date moved · Recorded 2026-10-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 09 Apr 2018 · actual
      Primary completion: 12 Feb 2027 · estimated
      Study completion: 12 Feb 2027 · estimated

      2021202220232024202520262027202820292030

      Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

      6 selected of 122 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 30 actual primary completions, 0 untyped primary completions, 2 past estimates, 45 outside the horizon, 0 contradictory dates.

      04 / Therapeutic focus

      Where the activity is

      151

      active trials in Oncology

      Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

      Active trials by primary therapeutic area

      • Oncology151 trials
      • Infectious Disease20 trials
      • Immunology & Inflammation15 trials
      • Respiratory12 trials
      • Metabolic/Endocrine/Nutrition6 trials
      • Cardiovascular3 trials
      • Dermatology2 trials
      • Ophthalmology2 trials
      • Gastroenterology & Hepatology1 trials
      • Neurology1 trials
      • Pain & Musculoskeletal1 trials
      • Psychiatry & Addiction1 trials
      • Renal & Urology1 trials
      • Unmapped3 trials
      • Healthy volunteers17 trials

      Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

      06 / Related companies

      All companies
      A

      AstraZeneca

      Shared indexed programme context · 1 selected asset

      B

      Bayer

      Shared indexed programme context · 1 selected asset

      G

      GSK

      Shared indexed programme context · 1 selected asset

      Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

      Sources, scope and methodology

      ClinicalTrials.gov lead-sponsor scope

      Canonical current-owner attribution covers 2,366 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Merck & Co. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion. The separately self-mapped Schering-Plough identity is excluded pending legal-lineage evidence. The supported Verona subset also appears on its operating-company page. Organon is excluded.

      ClinicalTrials.gov

      Attribution coverage

      2,366 distinct registry candidates produced 2,366 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

      Indexed enrichment

      2,238 scoped records have indexed enrichment and 128 do not. Missing enrichment does not remove a trial from cohort counts.

      Scope observation

      The successful attribution check completed at 2026-11-01T03:49:42.515Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot fed031f8c20fb5ada3516cfefe28c9d8a5936a9d08a92de6a302a46cd3cf8b2f.

      Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

      Dated canonical-attribution snapshot: 2,366 mapped lead-sponsored clinical studies across all statuses. 2,238 have indexed enrichment, 128 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

      Keep following
      what matters.

      Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

      Build your watch

      Choose what to track in the watch builder.